Short-Term Debt to Equity Ratio: Alterity Therapeutics Limited (ATHE)
Alterity Therapeutics (ATHE) focuses on developing therapies for neurodegenerative pathologies by utilizing molecules to control metal exchange in the brain. This chart of stock quotes demonstrates the debt-to-equity dynamics, which stands at 0.00. High barriers to entry are driven by patents and strict FDA oversight. Meanwhile, the company adheres to environmental standards regarding biohazardous waste disposal in its laboratories.
Analytical breakdowns for Alterity Therapeutics
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Alterity Therapeutics|ATHE - Long-Term Debt to Capital|Short-Term Debt to Equity Alterity Therapeutics|ATHE - Company Debts|Debt to Book Value Alterity Therapeutics Ltd.|ATHE - Amount of Long-Term Liabilities|Company Short-Term Debts Alterity Therapeutics|Quick Liquidity alteritytherapeutics.com
- company profitability and valuation multiples indicators:
General company analysis:Alterity Therapeutics Limited ATHE
This ratio measures the proportion of liabilities maturing within one year relative to equity, allowing for an assessment of liquidity risk and interest rate sensitivity. For Alterity Therapeutics (ATHE), which invests in combating neurodegeneration in Parkinson's disease, the trend of short-term liabilities to equity serves as an indicator of financial stability when funding costly cellular research.
Key competitors
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|Short-Term Debt to Capital denalitherapeutics.com|Short-Term Debt to Equity Harmony Biosciences Holdings, Inc. (HRMY)|Short-Term Debt to Equity BHVN (Biohaven Ltd)|Amylyx - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio TRVI (Trevi Corp)|Praxis Precision Medicines - Short-Term Debt to Capital|Current Liabilities to Capital anavex.com|CeriBell (CBLL) - Short-Term Debt to Equity|Prothena Biosciences - Ratio of Short-Term Indebtedness to Capital|ALEC (Alector Inc.) - Short-Term Debt to Capital|Annexon Biosciences Inc. (ANNX) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio OMER (Omeros Corporation)|Short-Term Loans to Capital Ratio NGNE|AC Immune SA - Short-Term Debt to Equity Ratio|Voyager Therapeutics Inc (VYGR) - Current Liabilities to Capital|NMRA: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital SCLX (Scilex Holding Company, Inc.)|TVGN (Tevogen Bio Holdings) - Short-Term Debt to Equity Ratio|ACOG: Short-Term Loans to Capital Ratio|CGTX (Cognition Therapeutics, Inc.) - Short-Term Debt to Capital|IKT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital SAVA|ASRT - Current Liabilities to Capital|Short-Term Debt to Equity Coya Therapeutics COYA|Ratio of Short-Term Indebtedness to Capital VTGN|Ovid Rx - Short-Term Debt to Capital|ABOS - Short-Term Debt to Capital|CervoMed Inc (CRVO) - Short-Term Debt to Equity|Current Liabilities to Equity CLNN (Clene)|PEPG (PepGen Inc) - Short-Term Debt to Capital|Current Liabilities to Capital jupiterneurosciences.com JUNS|Short-Term Debt to Equity Ratio RLMD (Relmada Therapeutics, Inc.)|Short-Term Debt to Capital Annovis Bio Inc (ANVS)|Grace Therapeutics - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio AIFF (Firefly Neuro)|ANEW Medical, Inc. - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient NeuroSense Therapeutics NRSN|RVPH: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio MetaVia|Short-Term Debt to Equity NeurAxis, Inc|Helius Medical Technologies Inc. (HSDT) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital PASG|Short-Term Debt to Capital bionomics.com.au (NEUP)|Minerva Neurosciences, Inc. - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio ATHA (Athira Pharma Inc)|Addex Therapeutics, Ltd. - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital ALZN (Alzamend Neuro, Inc.)|CYCN: Short-Term Debt to Capital|Current Liabilities to Capital Protagenic Therapeutics, Inc. (PTIX)|Short-Term Debt to Equity Pasithea Therapeutics Corp|Short-Term Debt to Capital Ratio CRGT (Cortigent Medical)|Short-Term Debt to Capital ATXI|BCLI - Current Liabilities to Capital|Cara Therapeutics, Inc. - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital chromocell.com CHRO|ELYM - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital ITCI (Intra-Cellular Therapies)|Longboard Pharma (LBPH) - Short-Term Debt to Equity|Current Liabilities to Capital Marinus Pharma (MRNS)|NKGN (NKGen Biotech, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital neurobopharma.com|Short-Term Debt to Equity Sage Therapeutics (SAGE)|Short-Term Debt to Equity SNPX (Synaptogenix Inc.)|Trevena, Inc - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio VIGL (Vigil Neuroscience Inc.)|Anew Medical, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital cerevel.com